维普中文期刊产品整合服务

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs.3 doses in young women

查看全文 作　　者：Yue-Mei [1]Hu;Meng [2]Guo;Chang-Gui [3]Li;Kai [1]Chu;Wen-Gang [2]He;Jing [4]Zhang;Jian-Xiang [4]Gu;Juan [3]Li;Hui [3]Zhao;Xiang-Hong [4]Wu;Bi-Zhen [5]Lin;Zhi-Jie [5]Lin;Xing-Mei [2]Yao;Ya-Fei [2]Li;Fei-Xue [2]Wei;Yue [2]Huang;Ying-Ying [2]Su;Feng-Cai [1]Zhu;Shou-Jie [2]Huang;Hui-Rong [5]Pan;Ting [2]Wu;Jun [2]Zhang;Ning-Shao [2]Xia 高影响力作者 机构地区：[1]Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009,China;[2]The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,Collaborative Innovation Center of Biologic Products,School of Public Health,Xiamen University,Xiamen 361102,China;[3]National Institute for Food and Drug Control,Beijing 102629,China;[4]Sheyang Center for Disease Control and Prevention,Sheyang 244300,China;[5]Xiamen Innovax Biotech Company,Xiamen 361022,China高影响力机构 出　　处：《Science China(Life Sciences)》索引2020年第63卷第4期,共10页高影响力期刊 基　　金：This work was supported by the National Natural Science Foundation of China(81673240,and U1705283);the Chinese National Major Scientific and Technological Special Project for“Significant New Drugs Development”(2018ZX09308010,2012ZX09101316);the Fujian Provincial Major Scientific and Technological Project(2015YZ0002)and Xiamen Innovax. 摘　　要：A new HPV-16/18 bivalent vaccine expressed by the Escherichia coli has been proven to be efficacious in adult women.A randomized,immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in China.Girls aged 9–14 years were randomized to receive 2 doses at months 0 and 6(n=301)or 3 doses at months 0,1 and 6(n=304).Girls aged 15–17 years(n=149)and women aged 18–26 years(n=225)received 3 doses.The objectives included noninferiority analysis of the IgG geometric mean concentration(GMC)ratio(95%CI,lower bound>0.5)to HPV-16 and HPV-18 at month 7 in girls compared with women.In the per-protocol set,the GMC ratio of IgG was noninferior for girls aged 9–17 years receiving 3 doses compared with women(1.76(95%CI,1.56,1.99)for HPV-16 and 1.93(95%CI,1.69,2.21)for HPV-18)and noninferior for girls aged 9–14 years receiving 2 doses compared with women(1.45(95%CI,1.25,1.62)for HPV-16 and 1.17(95%CI,1.02,1.33)for HPV-18).Noninferiority was also demonstrated for neutralizing antibodies.The immunogenicity of the HPV vaccine in girls receiving 3 or 2 doses was noninferior compared with that in young adult women. 关 键 词：immunobridging NONINFERIORITY human PAPILLOMAVIRUS vaccine ESCHERICHIA COLI GIRLS
相关文献

参考文献(33)

引证文献(32)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费